At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea , May 22, 2026 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taki